Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)
Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found